New University of Colorado study shows 1 in 15 American adults have been at a mass shooting

Stories from mass shooting survivors and their loved ones, as well as new research, are creating more awareness of gun violence. A new study from the University of Colorado Boulder shows that 1 in 15 US adults have been on the scene of a mass shooting. This study defines a mass shooting as an incident when four or more people are shot in a public space.
The research comes as those in the Boulder community gathered to remember the anniversary of the 2021 King Soopers shooting that took the lives of 10 people and impacted countless others.
That impact includes Erika Mahoney, whose father Kevin was killed while grocery shopping that day. Four years later, it's easy to see Mahoney's strong bond with her dad in family albums and frames throughout the house.
Mahoney showed CBS News Colorado some of those photos, describing them as she thumbed through.
"Here we're in the kitchen, and dad, I'm wearing my dad's giant jacket," Mahoney said. "It's motivating to see his face, but I also hear him saying, like, keep going."
As a former journalist, Mahoney is now dedicating her life to sharing stories like his and documenting the lasting impact of gun violence.
"The news covers [mass shootings] in the beginning, and the hardest part is those years in between where you're crying in the corner, or you can't go grocery shopping, or you are, you know, missing your dad and it's Father's Day," Mahoney said.
To showcase those moments and the generational pain that can follow a mass shooting, she's releasing a new podcast this spring.
Senseless
will feature more than a dozen people affected by gun violence in Boulder.
"At its heart, this podcast is truly a love letter to my dad, and it's about how we move forward after tragedy," Mahoney said.
One of her podcast guests will be David Pyrooz, a professor of sociology and criminologist at the Institute for Behavioral Science at CU Boulder. His episode will break down his new study that came up with the data behind the 1 in 15, or about 7% of US adults on average that have been at the scene of a mass shooting.
"It means you were in the direct vicinity to where you could see the shooter. There were bullets that were fired in your direction, or if you couldn't directly see the shooter, that you could hear the gunshots," Pyrooz said.
The study came to that number by surveying ten thousand people last year. The research also details that more than 2% of US adults have been injured during a mass shooting.
Pyrooz explains, "Mass shootings, you know, I know they occur across the world, but, you know, in the United States, there's just such a concerted interest and focus on it, and we should aim to understand this better."
Meanwhile, Mahoney continues to remember who her dad was and hopes the new data and personal stories together can showcase the realities of mass violence– and move the needle towards stopping them.
"If we can realize that this affects so many people far beyond really any number can show, because I'm not included in the data, and I was traumatized, and so, you know, we I think that the ripple effect is even so much bigger than we can imagine," Mahoney said.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

New York Post

a day ago

• New York Post

Bill Gates shares ‘next phase of Alzheimer's fight' as he speaks about his father's personal battle

Bill Gates is speaking out about his personal experience with Alzheimer's — and his hope for progress in fighting the disease. In an essay published this week on his blog at the Microsoft co-founder and tech billionaire, 69, reflected on the difficulty of spending another Father's Day without his dad, Bill Gates Sr. Advertisement The elder Gates passed away in 2020 at the age of 94 after battling Alzheimer's. 'It was a brutal experience, watching my brilliant, loving father go downhill and disappear,' Gates wrote in the blog post. Today, motivated by his own experience with the common dementia, Gates — who serves as chair of the Gates Foundation — is committed to working toward a cure for the common dementia, which currently affects more than seven million Americans, or one in nine people over 65. In his blog, Gates expressed optimism about the 'massive progress' being made in the fight against Alzheimer's and other dementias. Advertisement Last year, Gates said he visited Indiana University's School of Medicine in Indianapolis to tour the labs where teams have been researching Alzheimer's biomarkers. 5 Bill Gates (left) is speaking out about his personal experience with Alzheimer's — and his hope for progress in fighting the disease. Brian Ach 'I also got the opportunity to look under the hood of new automated machines that will soon be running diagnostics around the world,' he wrote. 'It's an exciting time in a challenging space.' One of the biggest breakthroughs in Alzheimer's research, according to Gates, is blood-based diagnostic tests, which detect the ratio of amyloid plaques in the brain. (Amyloid plaques, clumps of protein that accumulate in the brain, are one of the hallmarks of Alzheimer's.) Advertisement 'I'm optimistic that these tests will be a game-changer,' Gates wrote. 5 The elder Gates passed away in 2020 at the age of 94 after battling Alzheimer's. Bloomberg via Getty Images Last month, the U.S. Food and Drug Administration (FDA) approved the first blood-based test for patients 55 years and older, as Fox News Digital reported at the time. Traditionally, Gates noted, the primary path to Alzheimer's diagnosis was either a PET scan (medical imaging) or spinal tap (lumbar puncture), which were usually only performed when symptoms emerged. Advertisement The hope is that blood-based tests could do a better job of catching the disease early, decline begins. 5 Last month, the U.S. Food and Drug Administration approved the first blood-based test for patients 55 years and older, as Fox News Digital reported at the time. – 'We now know that the disease begins 15 to 20 years before you start to see any signs,' Gates wrote. 'A simple, accurate and easy-to-run blood test might one day make routine screening possible, identifying patients long before they experience cognitive decline,' he stated. Gates said he is often asked, 'What is the point of getting diagnosed if I can't do anything about it?' Start and end your day informed with our newsletters Morning Report and Evening Update: Your source for today's top stories Thanks for signing up! Enter your email address Please provide a valid email address. By clicking above you agree to the Terms of Use and Privacy Policy. Never miss a story. Check out more newsletters To that end, he expressed his optimism for the future of Alzheimer's treatments, noting that two drugs — Lecanemab (Leqembi) and Donanemab (Kisunla) — have gained FDA approval. 'Both have proven to modestly slow down the progression of the disease, but what I'm really excited about is their potential when paired with an early diagnostic,' Gates noted. Advertisement He said he is also hopeful that the blood tests will help speed up the process of enrolling patients in clinical trials for new Alzheimer's drugs. 5 The hope is that blood-based tests could do a better job of catching the disease early, decline begins. Monkey Business – To accomplish this, Gates is calling for increased funding for research, which often comes from federal grants. 'This is the moment to spend more money on research, not less,' he wrote, also stating that 'the quest to stop Alzheimer's has never had more momentum.' Advertisement 'There is still a huge amount of work to be done — like deepening our understanding of the disease's pathology and developing even better diagnostics,' Gates went on. 5 Microsoft Chairman Bill Gates, his wife Melinda, far left, his father Bill Gates Sr., and his step-mother Mimi Gates pose for a photo in 2007. AP Gates pointed out that when his father had Alzheimer's, it was considered a 'death sentence,' but that is starting to change. Advertisement 'I am blown away by how much we have learned about Alzheimer's over the last couple of years,' he wrote. 'I cannot help but be filled with a sense of hope when I think of all the progress being made on Alzheimer's, even with so many challenges happening around the world. We are closer than ever before to a world where no one has to watch someone they love suffer from this awful disease.'

Yahoo

3 days ago

• Yahoo

Boston Scientific's Q1 Earnings Call: Our Top 5 Analyst Questions

Boston Scientific's first quarter results were met with a positive market reaction following revenue and profit that surpassed Wall Street expectations. Management credited robust growth in its cardiology portfolio and the successful execution of a category leadership strategy spanning electrophysiology, WATCHMAN, and interventional cardiology products. CEO Michael Mahoney highlighted that double-digit expansion in the U.S. and momentum in Europe and Japan helped drive operational sales growth, while new product launches and increased adoption in emerging segments, such as FARAPULSE and Axios, also contributed to performance. Is now the time to buy BSX? Find out in our full research report (it's free). Revenue: $4.66 billion vs analyst estimates of $4.57 billion (20.9% year-on-year growth, 2% beat) Adjusted EPS: $0.75 vs analyst estimates of $0.67 (11.5% beat) Revenue Guidance for Q2 CY2025 is $4.88 billion at the midpoint, above analyst estimates of $4.79 billion Management raised its full-year Adjusted EPS guidance to $2.91 at the midpoint, a 2.5% increase Operating Margin: 19.8%, up from 17.5% in the same quarter last year Organic Revenue rose 18.2% year on year (13.1% in the same quarter last year) Market Capitalization: $150.5 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Robert Marcus (JPMorgan) asked about mitigating tariff headwinds. CFO Daniel Brennan explained the offset through increased revenue and targeted cost reductions, with no plans for major manufacturing shifts. Larry Biegelsen (Wells Fargo) questioned global electrophysiology market share. CEO Michael Mahoney acknowledged strong momentum and the goal of reaching #1, particularly through investments in China and Japan. Joanne Wuensch (Citi) inquired about WATCHMAN's growth and procedural trends. Mahoney and Dr. Ken Stein cited rapid adoption of concomitant procedures and favorable clinical data as key drivers. Travis Steed (Bank of America) asked about margin sustainability. Brennan attributed margin expansion to product mix and noted that tariffs will pressure gross margin in the second half, but full-year expansion is still expected. Danielle Antalffy (UBS) raised questions on the SoniVie acquisition's timing and potential. Mahoney described the clinical trial process and anticipated a multi-year path to realizing commercial contributions. In upcoming quarters, the StockStory team will monitor (1) continued growth and market share gains in electrophysiology and WATCHMAN, (2) progress on integrating new acquisitions and the resulting product launches, and (3) the company's ability to offset tariff-related cost pressures without sacrificing margin targets. Updates on key clinical trials and regulatory milestones will also be critical to tracking Boston Scientific's strategy execution. Boston Scientific currently trades at $101.38, up from $94.97 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

Yahoo

3 days ago

• Yahoo

Kristi Noem Rushed to the Hospital by Ambulance

Homeland Security Secretary Kristi Noem, 53, was taken to a hospital in Washington, D.C. on Tuesday after suffering from an allergic reaction. CNN was the first to report Tuesday that Noem had been transported to a hospital via ambulance, citing two sources familiar with the situation. In a subsequent statement to the Daily Beast, assistant secretary Tricia McLaughlin said: 'Secretary Noem had an allergic reaction today. She was transported to the hospital out of an abundance of caution. She is alert and recovering.' Noem was recently in California assisting Immigration and Customs Enforcement (ICE) with immigration raids. On Thursday, June 12, the homeland security secretary joined ICE officers during a raid in Huntington Park in Los Angeles County and took part in at least two operations, according to NBCLA. It was that same day that Noem hosted her now-infamous press conference on immigration, during which California Senator Alex Padilla was forcibly escorted out of the conference, then wrestled to the ground and handcuffed after attempting to ask Noem a question. More recently, Noem was spotted at President Donald Trump's sparsely-attended military birthday parade on Saturday, June 14. The following day, she posted a tribute to her husband, Bryon Noem, on X to celebrate Father's Day. On Monday, Health Secretary Robert F. Kennedy Jr. shared a photo of himself, Noem, and Sen. Rand Paul visiting the biological hazard labs at Fort Detrick on X. It appears that the visit occurred on Monday as well. Several Secret Service agents have been posted at entrances outside the hospital Noem was admitted to, according to CNN. This is a breaking news story and will be updated accordingly.